Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis

Published:2020-01-18 Issue:1 Volume:68 Page:56-63
ISSN:1355-008X
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Feng Guoli,Luo Yi,Zhang Qi,Zeng Feng,Xu Jie,Zhu Jingqiang

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s12020-019-02167-6.pdf

Reference33 articles.

1. C. Eheman, S.J. Henley, R. Ballard-Barbash, E.J. Jacobs, M.J. Schymura, A.M. Noone, L. Pan, R.N. Anderson, J.E. Fulton, B.A. Kohler, A. Jemal, E. Ward, M. Plescia, L.A. Ries, B.K. Edwards, Annual Report to the Nation on the status of cancer, 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118(9), 2338–2366 (2012). https://doi.org/10.1002/cncr.27514

2. B.R. Haugen, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer 123(3), 372–381 (2017). https://doi.org/10.1002/cncr.30360

3. R. Dadu, M.E. Cabanillas, Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol. 37(4), 335–356 (2012)

4. C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892–2899 (2006). https://doi.org/10.1210/jc.2005-2838

5. M. Schlumberger, M. Brose, R. Elisei, S. Leboulleux, M. Luster, F. Pitoia, F. Pacini, Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2(5), 356–358 (2014). https://doi.org/10.1016/S2213-8587(13)70215-8

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Tyrosine Kinase Inhibitors in Downstaging and Palliation in Patients with Advanced Differentiated Thyroid Cancer — A Multicentre study;Indian Journal of Surgical Oncology;2024-08-09

2. Short-Term Fatigue in Patients Receiving Radiotherapy after Breast Cancer. Systematic Review and Meta-Analysis;2024

3. The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer;International Journal of Molecular Sciences;2023-12-23

4. Thyroid Cancer: From Genes to Treatment – Recent Developments;Thyroid Cancer - The Road From Genes to Successful Treatment;2023-07-19

5. Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis;Oncology Letters;2023-05-10